Advertisement


Anthony M. Joshua, MBBS, PhD, on Low-Risk Prostate Cancer and Metformin: New Trial Data

2024 ASCO Annual Meeting

Advertisement

Anthony M. Joshua, MBBS, PhD, of Princess Margaret Cancer Centre, discusses results from the MAST study, which explored the question of whether metformin could reduce disease progression in men with low-risk prostate cancer who are undergoing active surveillance (LBA5002).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We designed the study back in 2012. It was a study of metformin, men with active surveillance for prostate cancer, and there was a lot of rationales as to why metformin would be useful in prostate cancer. There's laboratory studies that we've done speaking to the importance of metformin inhibiting mTOR as well as having epigenetic effects. There's data from other groups looking at the beneficial effect of metformin on the tumor microenvironment. There's epidemiological studies that suggest that diabetic men who take metformin do better for their prostate cancer treatment. There's combination studies that we've done demonstrating that, in some of the pivotal prostate cancer studies, the men who took metformin did better in the studies with abiraterone. So we put all those things together. We thought, well, metformin may be the perfect medication to give men undergoing active surveillance of prostate cancer. So from the period of 2013 to 2023, we randomised 400 men, approximately 204 on each arm to take metformin versus a matched placebo when they were undergoing active surveillance. And active surveillance is briefly, as per NCCN, very low to low risk criteria. Basically men with low volume Gleason 6 disease, and there's more details in the presentation, but those men were randomised over that period, and the endpoint was defined as either being therapeutic progression or pathological progression. The pathological progression was biopsies done at 18 and 36 months, and their therapeutic progression was any treatment for prostate cancer. And in brief, we found no difference between the arms, and in fact, there was a couple of concerning trends. One trend was that men who had a high BMI actually seemed to do worse on metformin for reasons we don't understand. And a priori, you would think those men would do better on metformin because they may lose weight, but that was not the case. And also there seemed to be a slight trend towards men progressing with higher Gleason scores who took metformin compared to those men who took placebo. This is a little bit worrying, and certainly we need to do more research to understand why this is the case. But this study was an academic study across 12 centers in Canada, funded through, essentially philanthropy, the Prostate Cancer Foundation, and the Canadian Cancer Association. So taken together, I think this has been a great academic effort. It will seed a lot of future research to understand the role of metformin and those types of drugs in men with and without diabetes for prostate cancer undergoing active surveillance.

Related Videos

Kidney Cancer

Laurence Albiges, MD, PhD, on Renal Cell Carcinoma: Biomarker Analysis of the IMmotion010 Study

Laurence Albiges, MD, PhD, of Gustave Roussy, Université Paris-Saclay, discusses phase III findings showing that high baseline serum KIM-1 levels were associated with poorer prognosis but improved clinical outcomes with atezolizumab vs placebo in patients with renal cell carcinoma at increased risk of recurrence after resection. Increased post-treatment KIM-1 levels were found to be associated with worse disease-free survival (Abstract 4506).

Lymphoma

Peter Riedell, MD, on DLBCL: Expert Commentary on Data From the ECHELON-3 Study

Peter Riedell, MD, of The University of Chicago, discusses phase III findings on the regimen of brentuximab vedotin in combination with lenalidomide and rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This therapy demonstrated a survival advantage in the third-line setting, but as this is an interim analysis, questions remain regarding long-term safety and duration of response, according to Dr. Riedell (Abstract LBA7005).

Prostate Cancer

Alicia Morgans, MD, MPH, and Samuel R. Denmeade, MD, on Prostate Cancer: Results From the TRANSFORMER Trial

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Samuel R. Denmeade, MD, of Johns Hopkins University School of Medicine, discuss a study showing that patients with metastatic castration-resistant prostate whose disease is progressing on abiraterone with androgen-receptor alterations detected in the blood may benefit from bipolar androgen therapy. Routine liquid biopsy testing may enable further adoption of bipolar treatment (Abstract 5003).

Breast Cancer

Sherene Loi, MD, PhD, on Early-Stage Breast Cancer: Weighing the Prognostic Value of ctDNA Detection

Sherene Loi, MD, PhD, of Peter MacCallum Cancer Centre, discusses a circulating tumor DNA (ctDNA) analysis from a cohort of patients with early-stage breast cancer who were enrolled in the monarchE trial. This large cohort was studied to look at the usefulness of a personalized tumor-informed assay for ctDNA detection in early stage high-risk patients (LBA507).

Leukemia

Mazyar Shadman, MD, MPH, on Chronic Lymphocytic Leukemia: Recruiting for the CELESTIAL-TNCLL Study

Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, discusses an ongoing phase III study of the BCL2 inhibitor sonrotoclax plus zanubrutinib vs venetoclax and obinutuzumab for patients with treatment-naive chronic lymphocytic leukemia. The investigators are recruiting internationally (see NCT06073821; Abstract TPS7087).

Advertisement

Advertisement




Advertisement